Abstracts

Stereotactic radiosurgery for palliative management of hepatocellular carcinoma associated with portal vein thrombosis

Background The life expectancy and treatment options for the patients with hepatocellular carcinoma HCC presented with portal vein thrombosis are frustrating. This study...

K. Abdelkarim ;

W. Hamed ;

M. ElGharib ;

G. Esmat ;

Mona Darwish , PhD;

M. Elebrashi ;

06/27/2022

PET/CT radiomic features to predict clinical outcomes in locally advanced pancreatic cancer

Background Innovative biomarkers to predict clinical outcomes in pancreatic cancer would be helpful in optimizing personalized treatment approaches. In this study, we ai...

06/27/2022

Comparison of the malignant predictors in intrahepatic and extrahepatic intraductal papillary neoplasm of bile duct

Background Intraductal papillary neoplasm of the bile duct (IPNB) is a precancerous lesion of cholangiocarcinoma, for which surgical resection is the most effective trea...

06/27/2022

Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): An academic, multicenter, single-arm, two-stage, phase 2 study

Background Therapeutic options after first-line treatment in patients with RAS mutant metastatic colorectal cancer (mCRC) are limited by poor clinical outcomes and lack ...

06/27/2022

Anal squamous cell carcinoma (ASCC) outcomes in clinical practice: From localized to metastatic setting

Background Anal cancer is an infrequent neoplasm, usually diagnosed at localized stages. A multidisciplinary approach involving chemoradiotherapy (CRT) and surgery is ne...

06/27/2022

GOBLET: A phase 1/2 multiple indication signal finding and biomarker study in advanced gastrointestinal cancers treated with pelareorep and atezolizumab – safety and preliminary response results

Background In GI cancers, checkpoint inhibitors are only effective in patients with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) tumors. O...

06/27/2022

Unrecognized development of chemoresistance and/or distant metastases during induction chemotherapy for pancreatic adenocarcinoma

Background Induction Chemotherapy (IC) is often used in the treatment of pancreatic cancer (PC) and concurrent chemoradiotherapy (CRT), when given, usually follows the c...

06/27/2022

RETRO-TAS, a retrospective observational study of rifluridine/tipiracil in chemorefractory metastatic colorectal cancer

Background Trifluridine/tipiracil (TAS-102) is an oral combination of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylas...

06/27/2022

Impacts of salvage chemotherapy after nivolumab therapy (NIVO): A REVIVE substudy

Background The primary endpoints met in the REVIVE study have been previously reported, demonstrating the chemotherapeutic efficacy after the progression on NIVO therapy...

06/27/2022

Non-invasive HER2 status diagnosis in gastric cancer using surrogate DNA methylation markers

Background Gastric cancer (GC) is the fifth most common and fourth most lethal cancer worldwide. Unlike other cancer types, e.g., lung or breast cancer, very few targete...

06/27/2022